Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15121399 | 1.00 | KMT2A (0.31) | KMT2A | |
| SCHEMBL11203408 | 1.00 | — | — | |
| SCHEMBL4456992 | 1.00 | KMT2A (0.31) | KMT2A | |
| SCHEMBL15121408 | 1.00 | KMT2A (0.31) | KMT2A | |
| SCHEMBL864214 | 0.97 | — | — | |
| SCHEMBL3147175 | 0.89 | — | — | |
| SCHEMBL9015248 | 0.89 | — | — | |
| SCHEMBL42827 | 0.89 | — | — | |
| SCHEMBL28806510 | 0.86 | — | — | |
| SCHEMBL11325594 | 0.84 | ACHE (0.32) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156050-A1 | Carboxamine compounds, methods and compositions for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2002-10-24 | — | — | US | disclosed |
| US-6395749-B1 | Carboxamide compounds, methods, and compositions for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1077944-A1 | CARBOXAMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059973-A1 | CARBOXAMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156050-A1 | Carboxamine compounds, methods and compositions for inhibiting PARP activity | PARP1, PARP3, PARP4 | KMT2A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.